ArticleJACC. Advances2026
Inflammatory Biomarkers and ECG Repolarization Metrics: Sudden Death in Heart Failure With Reduced Ejection Fraction.
Article in JACC. Advances, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
11 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
backgroundSudden cardiac death (SCD) is a leading cause of mortality in heart failure with reduced ejection fraction (HFrEF). Although prolonged corrected QT (QTc) interval is associated with inflammation and SCD, the association between inflammatory biomarkers, electrocardiogram (ECG) repolarization metrics and SCD remains unclear in HFrEF.
objectivesThe objective of the study was to assess the relationship between ECG repolarization intervals, inflammation, and SCD in HFrEF.
methodsWe evaluated 4,391 patients with HFrEF and recent decompensation in the VICTORIA trial who had core lab-adjudicated ECGs and baseline biomarkers. We assessed whether interleukin-6, growth differentiation factor-15, and high-sensitivity C-reactive protein (hsCRP) were associated with SCD and an association between QTc interval prolongation and SCD. JTc interval was also included and defined as QTc minus the QRS duration. Cox proportional hazards and linear regression models were used.
resultsJTc interval (HR: 0.97 per 10 ms; 95% CI: 0.94-1.00; P = 0.043), but not QTc interval, was associated with SCD. All 3 biomarkers were associated with increased SCD risk in univariable analysis, but only hsCRP remained significant in multivariable models (HR: 1.20 per doubling; P < 0.001). Growth differentiation factor-15 was independently associated with QTc and JTc intervals. When each inflammatory biomarker was added separately to the covariate-adjusted JTc interval model, hsCRP provided the greatest prognostic value (16% new information; P < 0.001).
conclusionsInflammatory biomarkers, particularly hsCRP, are independently associated with SCD in patients with HFrEF and provide prognostic value beyond ECG parameters. These findings suggest that inflammation likely contributes to SCD risk through pathways distinct from repolarization prolongation. Biomarkers such as hsCRP may be useful to incorporate into risk stratification.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.